BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31257015)

  • 1. Extended Adjuvant Therapy With Aromatase Inhibitors for Early Breast Cancer: A Meta-analysis of Randomized Controlled Trials.
    Xu L; Zhang Z; Xiang Q; Liu Q; Duan X; Liu Y; Cui Y
    Clin Breast Cancer; 2019 Oct; 19(5):e578-e588. PubMed ID: 31257015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials.
    Qian X; Li Z; Ruan G; Tu C; Ding W
    Breast Cancer Res Treat; 2020 Jan; 179(2):275-285. PubMed ID: 31606823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials.
    Corona SP; Roviello G; Strina C; Milani M; Madaro S; Zanoni D; Allevi G; Aguggini S; Cappelletti MR; Francaviglia M; Azzini C; Cocconi A; Sirico M; Bortul M; Zanconati F; Giudici F; Rosellini P; Meani F; Pagani O; Generali D
    Breast; 2019 Aug; 46():19-24. PubMed ID: 31051411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ; Dawson C; Lawrence DH; Bliss JM
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    Khosrow-Khavar F; Filion KB; Al-Qurashi S; Torabi N; Bouganim N; Suissa S; Azoulay L
    Ann Oncol; 2017 Mar; 28(3):487-496. PubMed ID: 27998966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
    Li L; Chang B; Jiang X; Fan X; Li Y; Li T; Wu S; Zhang J; Kariminia S; Li Q
    BMC Cancer; 2018 Oct; 18(1):977. PubMed ID: 30314452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
    Rydén L; Heibert Arnlind M; Vitols S; Höistad M; Ahlgren J
    Breast; 2016 Apr; 26():106-14. PubMed ID: 27017249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis.
    Goldvaser H; AlGorashi I; Ribnikar D; Seruga B; Templeton AJ; Ocana A; Amir E
    Cancer Treat Rev; 2017 Nov; 60():53-59. PubMed ID: 28881223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity of extended adjuvant endocrine with aromatase inhibitors in patients with postmenopausal breast cancer: A Systemtic review and Meta-analysis.
    Zhao F; Ren D; Shen G; Ahmad R; Dong L; Du F; Zhao J
    Crit Rev Oncol Hematol; 2020 Dec; 156():103114. PubMed ID: 33045493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
    Conte P; Frassoldati A
    Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis.
    He P; Li J; Chen M; Huang M; Qiu Y; Cai Q; Lin Y; Wang C; Fu F
    Breast Cancer Res Treat; 2024 Jan; 203(1):13-28. PubMed ID: 37787817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant aromatase inhibitor therapy: outcomes and safety.
    Janni W; Hepp P
    Cancer Treat Rev; 2010 May; 36(3):249-61. PubMed ID: 20133065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
    Bartlett JMS; Ahmed I; Regan MM; Sestak I; Mallon EA; Dell'Orto P; Thürlimann B; Seynaeve C; Putter H; Van de Velde CJH; Brookes CL; Forbes JF; Viale G; Cuzick J; Dowsett M; Rea DW;
    Eur J Cancer; 2017 Jul; 79():129-138. PubMed ID: 28494403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatase inhibitors plus ovarian function suppression versus tamoxifen plus ovarian function suppression for premenopausal women with early stage breast cancer: a systematic review and meta-analysis.
    Meng J; Wang X; Guan Y; Zhang D
    Ann Palliat Med; 2020 Jul; 9(4):2294-2302. PubMed ID: 32434371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 10 years or less of extended adjuvant endocrine therapy for postmenopausal breast cancer patients: A systematic review and network meta-analysis.
    Petrelli F; Cavallone M; Dottorini L
    Eur J Cancer; 2023 Nov; 193():113322. PubMed ID: 37769477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis.
    Goldvaser H; Barnes TA; Šeruga B; Cescon DW; Ocaña A; Ribnikar D; Amir E
    J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.